---
title: "Uncovering Potential: Masimo's Earnings Preview"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276912788.md"
description: "Masimo (NASDAQ:MASI) is set to release its quarterly earnings report on February 26, 2026, with analysts expecting an EPS of $1.49. The company previously beat EPS estimates by $0.12, but shares dropped 4.61% the following day. Currently trading at $175.35, Masimo's stock is down 5.77% over the past year, raising concerns among long-term investors. Analysts' ratings and price targets will be crucial for market sentiment ahead of the earnings announcement."
datetime: "2026-02-25T16:02:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276912788.md)
  - [en](https://longbridge.com/en/news/276912788.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276912788.md)
---

# Uncovering Potential: Masimo's Earnings Preview

Masimo (NASDAQ:MASI) will release its quarterly earnings report on Thursday, 2026-02-26. Here's a brief overview for investors ahead of the announcement.

Analysts anticipate Masimo to report an **earnings per share** (EPS) of $1.49.

The market awaits Masimo's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.

It's important for new investors to understand that guidance can be a significant driver of stock prices.

### Performance in Previous Earnings

Last quarter the company beat EPS by $0.12, which was followed by a 4.61% drop in the share price the next day.

Here's a look at Masimo's past performance and the resulting price change:

**Quarter**

**Q3 2025**

**Q2 2025**

**Q1 2025**

**Q4 2024**

**EPS Estimate**

1.20

1.23

1.21

1.42

**EPS Actual**

1.32

1.33

1.36

1.80

**Price Change %**

\-5.00

\-12.00

\-7.00

12.00

![eps graph](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772035323_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

### Stock Performance

Shares of Masimo were trading at $175.35 as of February 24. Over the last 52-week period, shares are down 5.77%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.

### Analyst Observations about Masimo

For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Masimo.

Analysts have given Masimo a total of ratings, with the consensus rating being . The average one-year price target is $, indicating a potential .

To track all earnings releases for Masimo visit their earnings calendar on our site.

_This article was generated by Benzinga's automated content engine and reviewed by an editor._

### Related Stocks

- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [MASI.US](https://longbridge.com/en/quote/MASI.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [AbbVie (NYSE:ABBV) Issues Q1 2026 Earnings Guidance](https://longbridge.com/en/news/282227475.md)
- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)
- [CVRx preliminary Q1 revenue rises 20%, gross margin improves](https://longbridge.com/en/news/282541849.md)
- [RBC Capital Sticks to Their Buy Rating for Edwards Lifesciences (EW)](https://longbridge.com/en/news/282768248.md)
- [BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug](https://longbridge.com/en/news/282702171.md)